GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: emapalumab-lzsg | Gamifant® | NI-0501 | NI0501
emapalumab is an approved drug (FDA (2018))
Compound class:
Antibody
Comment: Emapalumab (NI-0501) is a fully human monoclonal antibody that targets interferon gamma (IFNγ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2006109191, and in which NI-0501 is confirmed as an exemplary antibody [2]. |
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. US FDA (2018) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 10319 | emapalumab |
Synonyms ![]() |
| emapalumab-lzsg | Gamifant® | NI-0501 | NI0501 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 666 |
| Other databases | |
| GtoPdb PubChem SID | 318164814 |
| Search PubMed clinical trials | emapalumab |
| Search PubMed titles | emapalumab |
| Search PubMed titles/abstracts | emapalumab |